AI-researched · adversarially reviewed · human-checked · corrections public
BEFORE YOU READ — HOW DO YOU RULE?
The Verdict
For severe depression, antidepressants genuinely help and can be part of saving a life — the effect is real, replicated, and grows with severity. For mild, everyday misery, the average benefit over placebo is small enough that researchers argue about whether patients can feel it — yet that is exactly where much of the prescribing happens. The drugs were marketed for decades on a "chemical imbalance" story the evidence never supported; withdrawal is real and was long downplayed; and stopping should be planned with a clinician, never done abruptly.
Conditional
MODERATE EVIDENCE
§ What it actually does
Where the evidence says yes
strongBeats placebo for major depression across 500+ trials of 21 drugs — the effect exists; the argument is about size, not existence.
strongHelps more as severity rises: in severe depression the benefit is clinically meaningful; this is where the drugs earn their keep.
strongAlmost certainly prevents relapse in people who have responded — continuation roughly halves relapse rates in trials.
strongWorks for more than depression: solid evidence in anxiety disorders, OCD, and panic disorder.
§ What it doesn't do
Where the marketing outruns the data
strongDoes not do much, on average, for mild depression — the average drug-placebo gap is a few points on a 52-point scale, below common thresholds for what patients notice.
contradictedDoes not fix a "serotonin deficiency," despite a generation of marketing: the 2022 umbrella review found no consistent evidence depression is caused by low serotonin. The drugs can work without the story being true.
strongDoes not work quickly or universally: weeks to onset, and in the largest real-world sequence (STAR*D) roughly a third of patients hadn't remitted after multiple drug steps.
strongThere is no evidence the published record told the whole story: a third of FDA-registered trials went unpublished or were spun — the published literature made the drugs look better than the full data did.
§ The Money Map
Who profits, stage by stage
The golden ageSSRIs were pharma's biggest franchise for two decades. The "chemical imbalance" narrative was a marketing invention that outlived its evidence — it made a prescription feel like insulin for the brain.
The evidence machineIndustry-funded trials, ghost-written papers, and selective publication (documented in the Turner NEJM analysis) inflated apparent efficacy for years.
Today's pipelinePatents expired; generics are cheap. The new money is in telehealth subscription prescribing (questionnaire → refill), and in patented successors (esketamine et al.) priced like the old days.
The other side's moneyAudit the critics too: "get off your meds" content sells courses, supplements, and books. Withdrawal-scare monetization is real, and it kills people who quit abruptly.
This pageNo pharma, no telehealth, no "natural mood" supplements. See "How we make money."
§ The other side
The strongest case against this verdict
The strongest case against our verdict\'s skeptical half: averages hide responders. A drug with a modest average effect can still transform the meaningful minority who respond strongly, and clinicians cannot identify them in advance — so restricting access to "severe only" would deny real help to some mild-moderate patients. Small average effects on symptom scales can also understate functional benefit (getting to work, staying alive). And placebo response in trials is partly the ritual of care — the real-world comparison isn\'t drug vs elaborate placebo ceremony, it\'s drug vs a six-minute GP visit and nothing.
§ Symmetric harms
Harms of using it — and of avoiding it
If you use it
Sexual dysfunction is common, dose-related, and under-disclosed; a subset report it persisting after stopping (PSSD) — acknowledged by EU regulators.
Withdrawal/discontinuation symptoms are real and can be severe and prolonged after long-term use; tapering needs to be slow and planned.
Emotional blunting reported by a substantial minority.
In under-25s: an activation/suicidality signal early in treatment (the FDA black-box warning) — needs close monitoring, not casual telehealth refills.
Elderly: falls, hyponatremia, bleeding interactions.
If you avoid it
Untreated severe depression is lethal: suicide, and a mortality/morbidity burden across every organ system. This is the strongest harm-of-avoiding on this page.
Refusing continuation after response roughly doubles relapse risk.
Quitting abruptly because of something you read — including this page — is the worst of all options: withdrawal + relapse together.
§ The Minority Report
Who gets hurt when it goes right for everyone else
Both tails get hurt: people medicated who barely benefit, and people scared off medication who badly needed it.
Mildly depressed patients on long-term SSRIs: absorbing sexual side effects, blunting, and eventual withdrawal for an average benefit near the noise floor.
Under-25s started via questionnaire telehealth: the black-box group, with the least monitoring.
Undiagnosed bipolar patients: an SSRI alone can precipitate mania — screening is routinely skipped in fast prescribing.
Long-term users never told about withdrawal: some end up in years-long tapers; their suffering was officially minimized for decades.
Severely depressed people talked out of treatment by anti-medication content: the other minority, and the one that dies most.
How to tell if you might be in this group: Ask: how severe is my depression, formally scored? Am I under 25 (monitoring plan)? Any bipolar screening? What is the taper plan for the eventual exit, and what functional change will tell us in 8 weeks whether this is working?
§ The alternatives ledger
Everything else, judged by the same standards
strong
Psychotherapy (CBT and related) Comparable to drugs for mild-moderate depression, with benefits that persist after treatment ends — the durability drugs lack. Access and cost are the honest obstacles.
moderate
Exercise Likely a genuine antidepressant for mild-moderate cases in meta-analyses — unprofitable, so nobody markets it to you.
strong
Lithium, ECT, ketamine — for severe/refractory illness The heavy artillery has strong evidence exactly where SSRIs run out: lithium prevents suicide; ECT works in severe depression; ketamine acts in hours (and is being commercialized accordingly).
moderate
St. John's Wort May work for mild depression (German trials) — and interacts dangerously with many drugs, including birth control and SSRIs themselves. "Natural" is not "inert."
§ Take it to a human
Questions for your doctor
What is my measured severity, and what does the evidence say for that severity specifically?
Can we try psychotherapy or exercise first — or alongside?
What is the exit plan: when do we reassess, and how would we taper?
Have I been screened for bipolar disorder before starting an SSRI?
Who responds and why — no reliable predictor exists; prescribing remains trial-and-error.
True prevalence of persistent post-treatment sexual dysfunction.
Long-term (decade+) outcomes of continuous use versus episodic treatment.
§ Corrections
Updates & corrections — public, dated, proud
No corrections yet. Found an error? Challenge it — substantiated challenges are corrected within 48 hours and logged here permanently. Submit a challenge →
§ We dissect ourselves too
How WE make money
This pageNo pharmaceutical advertising, no telehealth referral fees, no supplement affiliates. Health.AI earns from optional Pro subscriptions. If that changes, this box changes first.
Demand the next dissection
Any disease, drug, supplement, or practice. The queue decides what we dissect next.
If you're struggling right now: this page is about evidence, not about you — and no verdict is a reason to face a crisis alone. India: iCall 9152987821 · Tele-MANAS 14416. US: call or text 988. Elsewhere: your local emergency number. If you're on medication and want to stop, do it with a clinician — never abruptly.